Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CStone Pharmaceuticals ( (HK:2616) ) just unveiled an announcement.
CStone Pharmaceuticals has entered an exclusive licensing agreement with Istituto Gentili to commercialize its anti-PD-L1 monoclonal antibody, sugemalimab, across Western Europe and the UK. This partnership allows CStone to receive up to $192.5 million in milestone payments and recognizes close to 50% of net sales as revenue. The agreement expands sugemalimab’s reach to over 60 countries, enhancing its availability amid global pricing uncertainties in the US. This move strengthens CStone’s market position and aims to address unmet medical needs in oncology, particularly for non-small cell lung cancer (NSCLC).
More about CStone Pharmaceuticals
CStone Pharmaceuticals is a biopharmaceutical company incorporated in the Cayman Islands, focusing on developing and commercializing innovative immunotherapy treatments, particularly in oncology. The company is expanding its global reach through strategic partnerships to maximize the clinical and commercial value of its products, such as sugemalimab.
Average Trading Volume: 11,903,751
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.96B
Find detailed analytics on 2616 stock on TipRanks’ Stock Analysis page.